Adalimumab Use in the Treatment of Hidradenitis Suppurativa.

Abstract

Hidradenitis suppurativa is a chronic, recurrent, suppurative skin disease with an incidence of 6 cases per 100,000 people per year. Adalimumab has become the only approved and labeled medication for the treatment of hidradenitis suppurativa. The aim of this study is to verify the relationship between adalimumab and the treatment of hidradenitis suppurativa. In this study, a literature review was planned, by collecting journals which would allow a better research on the subject, by finding articles in PubMed, Science Direct and Google Scholar databases. The efficacy of adalimumab in hidradenitis suppurativa was evaluated using controlled trials and placebo. Clinical response showed that adalimumab is more efficient than palcebo in treating the disease. It is clear that adalimumab is a safe treatment option for patients with moderate to severe hidradenitis suppurativa, where it showed a satisfactory clinical response for any population with Hurley stage and a significant reduction of lesions.